×

DETECTING COMPLEMENT ACTIVATION

  • US 20120315266A1
  • Filed: 05/01/2012
  • Published: 12/13/2012
  • Est. Priority Date: 11/02/2010
  • Status: Active Grant
First Claim
Patent Images

1. A method comprising steps ofdetecting in a sample from a subject a level of intact C3, wherein the detecting involves specific interaction between the intact C3 and a non-cross-reactive antibody thereto;

  • comparing the detected level with a reference level, which reference level is within a range of about 350 ug/ml to about 1,700 ug/ml;

    wherein determination that the detected level is below the reference level indicates that the subject is suffering from or susceptible to undesirable and/or pathologic complement activation; and

    administering treatment to treat undesired complement activation if the detected level is below the reference level.

View all claims
  • 2 Assignments
Timeline View
Assignment View
    ×
    ×